The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study.
Brian G. Czito
Consultant or Advisory Role - Pfizer
Research Funding - AbbVie
Mary Frances Mulcahy
No relevant relationships to disclose
William R. Schelman
No relevant relationships to disclose
Houman Vaghefi
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Gayle S. Jameson
No relevant relationships to disclose
Angela Deluca
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Hao Xiong
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Wijith Munasinghe
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Matthew W. Dudley
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Kyle D. Holen
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Michael Michael
No relevant relationships to disclose